<DOC>
	<DOCNO>NCT01559818</DOCNO>
	<brief_summary>Patients previously enrol Study IMM-101-001 provide inform consent eligible participate study . Once eligibility confirm , full medical history cover period completion Study IMM-101-001 date take . The treatment regimen IMM-101 one dose give every 4 week close interval permit due practical logistic consideration . The dose interval may modify discretion Investigator provide minimum period dose less 14 day . The overall objective determine long term safety profile IMM-101 administer intradermally extend use .</brief_summary>
	<brief_title>A Long Term Follow Study Patients Who Previously Took Part Phase I Study IMM-101-001</brief_title>
	<detailed_description>This open-label long term follow study . The study consist two phase : 1 . Screening enrolment Patients , provide inform consent , participate screen period 28 day establish eligibility . Once eligibility confirm full disease treatment history cover period completion Study IMM-101 001 date take . 2 . Treatment Patients receive ongoing treatment every 4 week close interval permit due practical logistic consideration death withdrawal , unless therapy contraindicate , patient wish continue study terminate Sponsor . At point elapsed period IMM-101 dose less 14 day . Patients may choose withdraw study time reason . IMM-101 stop dose regimen reduce felt necessary Investigator and/or patient ( e.g. , intolerable injection site reaction ) . In event injection site reaction Grade 3 , and/or significant ulceration , tenderness lymphadenopathy observe , discretion Investigator , patient may administer half dose study drug ( i.e. , single 0.05 mL intradermal injection IMM-101 ) time injection may delay . If dosing interval increase , patient still attend study site safety assessment preferably every 3 month , possible , every 6 month minimum . The blood sample exploratory analysis continue take every 6 month . Any change dose study drug administer frequency dose administration record patient 's case report form ( CRF ) . In case withdrawal , separate consent seek allow continue collection patient status .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patient previously enrol Study IMM 101 001 Patient give consent make disease treatment history intervene period completion Study IMM101001 enrollment study available Sponsor Patient give sign informed consent participation study Female patient childbearing potential , opinion Investigator , use approve method birth control ( e.g. , physical barrier [ patient partner ] , contraceptive pill patch , spermicide barrier , intrauterine device [ IUD ] ) . Those patient utilise hormonal contraceptive must use method least three month additional barrier contraception ( describe ) discontinue use concomitantly hormonal contraception . Patient nonchildbearing potential define 12 month amenorrhoea surgically sterile . Female patient pregnant , breast feeding planning pregnancy course study . A pretreatment urine pregnancy test measure human chorionic gonadotrophin ( hCG ) must negative . Patient unable unwilling comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>